Laura Bagarella


New York

Laura Bagarella is a partner in the New York office and member of the Compensation and Benefits Group.

Laura’s practice focuses on the executive compensation and employee benefits aspects of domestic and cross-border public and private mergers and acquisitions, spin-offs, divestitures, IPOs, minority investments and other corporate transactions. She also regularly advises on the design, taxation, disclosure, negotiation, implementation and ongoing administration of equity and cash incentive programs, deferred compensation plans, severance and other change in control and retention arrangements for both public and private companies, including private equity backed companies. In addition, Laura routinely represents companies and executives in the negotiation of employment, consulting, separation, and other compensation arrangements.

Before joining the firm, Laura practiced at Cleary Gottlieb Steen & Hamilton LLP.

  • Warburg Pincus and its portfolio companies on a variety of transactions, including:

    • its acquisition, together with Advent International, of BioPharma Solutions from Baxter Pharmaceutical for $4.25 billion*
    • its investment, along with Berkshire Partners, in Ensemble Health Partners*
    • its investments in iNRCORE, Duravant, Infinite Electronics, Sotera Health, Gabriel Brothers, Consolidated Precision Products, FlexXray, Certified Laboratories, Sundyne and Hygiena*
    • the sale of Wencor Group LLC, a Warburg Pincus portfolio company, to Heico Corporation for $2.05 billion*
    • the sale of Summit Health-CityMD, a Warburg Pincus portfolio company, to VillageMD for $8.9 billion*

    Carlyle in its investment in Medforth Global Healthcare Education*

    • Wafra in its acquisition of Contract Leasing Corporation*
    • T-Mobile in its pending up to $1.35 billion acquisition of Ka’ena and its subsidiaries and brands, Mint Mobile, Ultra Mobile, and Plum*
    • Tempur Sealy in its pending $4 billion acquisition of Mattress Firm*
    • American Tower in its $10.1 acquisition of CoreSite Realty Corporation*
    • Allergan on its proposed $160 billion combination with Pfizer*

    * indicates experience prior to joining Orrick